# Avidicure

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avidicure-b-v

- Industry: Healthcare
- Headquarters: Oegstgeest, Netherlands
- Website: www.avidicure.com/
- Total disclosed funding: $50M
- Latest round: Seed (Apr 14, 2025)
- Investors on record: 6

## About

Based in the Netherlands, Avidicure B.V. develops innovative biopharmaceutical products, focusing on dual agonistic multifunctional antibodies to modulate immune responses against various cancers, highlighting their commitment to advancing oncology treatments.Avidicure B.V. specializes in biopharmaceutical innovations, particularly in the field of oncology. Founded in 2022 and headquartered in Oegstgeest, Netherlands, the company has successfully completed one funding round. The Seed funding round on April 14, 2025, raised USD 50 mn, led by EQT Life Sciences with participation from Kurma Partners, BioGeneration Ventures, BOM Brabant Ventures, Curie Capital, and V-Bio Ventures. Govert Schouten, the founder, has a background in the biopharmaceutical sector, contributing to the company's strategic vision.Avidicure specializes in innovative biopharmaceutical products, principally their proprietary dual agonistic multifunctional antibodies known as "AVC-Boosters." These antibodies are engineered to modulate the immune system, effectively targeting both innate and adaptive immune responses to fight various cancers. Their flagship product, AVC-S-101, is under development for non-small cell lung cancer and other indications. Avidicure's AVC-Booster platform utilizes a proprietary antibody scaffold integrated with co-stimulatory domains to stimulate immune responses specifically within the tumor microenvironment, thus enhancing therapeutic efficacy while reducing systemic toxicity risks. The company targets a global client base that includes oncologists, hospitals, and research institutions across major markets such as North America, Europe, and parts of Asia.Avidicure's revenue model is built around partnerships with healthcare providers and research organizations, engaging primarily in business-to-business transactions. The company supplies its AVC-Boosters to hospitals, oncology clinics, and pharmaceutical firms involved in cancer treatment development. Revenue is generated from AVC-Booster sales, with potential additional income from strategic partnerships involving milestone payments or royalties linked to successful product development and commercialization. While specific pricing details for AVC-Boosters are not publicly disclosed, the company focuses on high-value oncology treatments that align with industry standards for advanced biopharmaceutical therapies.In April 2025, Avidicure B.V. raised USD 50 mn in Seed funding led by EQT Life Sciences, aimed at developing a novel multipurpose antibody treatment for cancer. The company plans to expand its product offerings and is exploring new markets, particularly in North America and Europe, enhancing its reach within the oncology sector. The funds will be utilized to support the creation of innovative treatments that address unmet needs in cancer care.

## Funding rounds

- Seed, Apr 14, 2025, $50M — EQT Life Sciences, BioGeneration Ventures, Kurma Partners, BOM Brabant Ventures, V-Bio Ventures, Curie Capital

## Investors

- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Seed
- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Seed
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Seed
- BOM Brabant Ventures (https://capitalatlas.ai/funds/bom-brabant-ventures) — Seed
- V-Bio Ventures (https://capitalatlas.ai/funds/v-bio-ventures) — Seed
- Curie Capital (https://capitalatlas.ai/funds/curie-capital) — Seed